Containing Discrete Coated Particles Pellets, Granules, Or Beads Patents (Class 424/458)
  • Patent number: 10413525
    Abstract: The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: September 17, 2019
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Ravindra Agarwal, Tarun Singhal, Ravi Kochhar
  • Patent number: 10314794
    Abstract: The invention relates to a drug sustained-release composition, particularly a sustained-release composition comprising metoprolol and preparation method thereof. The invention also relates to a combination product comprising a sustained-release composition comprising metoprolol and a pharmaceutical composition comprising hydrochlorothiazide. The sustained-release composition comprising metoprolol according to the invention eliminates the phenomena of delayed release of such sustained-release compositions in the prior art, has a better drug release curve, and also have the advantages such as simple formula, easy operation, stable quality, strong controllability, and good reproducibility, and therefore have good application prospects.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: June 11, 2019
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Chunsheng Gao, Yuli Wang, Meiyan Yang, Li Shan, Jingjing Dai, Yong Qian, Yan Qiu
  • Patent number: 10285944
    Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: May 14, 2019
    Assignee: ALFASIGMA S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Ernesto Palazzini, Villiam Zamboni, Maria Rosaria Pantaleo
  • Patent number: 10213453
    Abstract: Oral formulation of particles made of an agglomeration of a plurality of seed granules or a single seed granule both surrounded by three layers and an outer gel coating. The seed granules are made of calcium carbonate with microscopic fissures. Disposed inside the fissures and in the interstitial spaces of the agglomerate seed granules are microscopic particles of alkali metal salts and other ions. Coating the agglomerate or single seed granules is an alkaline-resistant first layer made of microcrystalline cellulose and croscarmellose sodium that binds and protects the surrounding second layer. Surrounding the first layer is a second layer comprising a mixture of a flavonoid and polysaccharide or polypeptide binder or polymer gel. Surrounding the second layer is a third layer made of alkaline earth metal salt particles holding alkali metal hydroxide ions within a polysaccharide or polymer gel. Surrounding the third layer is at least one outer gel layer.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: February 26, 2019
    Inventors: Steven Loyd, George Blouin, Newsha Farahani, Robert Burns
  • Patent number: 10189616
    Abstract: A system and method for determining an optimal combination drug product for a particular patient includes a processor that receives patient information and determines an optimal combination drug product based on the received information. A system which can provide information regarding predicted events or pathologies based on received patient information and guidance on subsequent steps to ameliorate, treat or intervent. A drug production device includes a plurality of drug containers, each of which are coupled to a drug dispensing channel. A controller controls the dispensing of drug through each channel, and a combination drug product is produced from the dispensed drugs. A combination drug product includes a plurality of discrete units of a first drug, and a plurality of discrete units of a second drug. A transdermal patch includes a plurality of drug compartments, each containing a quantity of drug product, and a controller for controlling the release of drugs from each compartment.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: January 29, 2019
    Inventor: Daniel L. Kraft
  • Patent number: 10016391
    Abstract: The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: July 10, 2018
    Assignee: Sun Pharmaceutical Industries, Ltd.
    Inventors: Ravindra Agarwal, Tarun Singhal, Ravi Kochhar
  • Patent number: 9808478
    Abstract: Oral formulation of particles made of an agglomeration of a plurality of seed granules or a single seed granule both surrounded by three layers and an outer gel coating. The seed granules are made of calcium carbonate with microscopic fissures. Disposed inside the fissures and in the interstitial spaces of the agglomerate seed granules are microscopic particles of alkali metal salts and other ions. Coating the agglomerate or single seed granules is an alkaline-resistant first layer made of microcrystalline cellulose and croscarmellose sodium that binds and protects the surrounding second layer. Surrounding the second layer is a third layer made of alkaline earth metal salt particles holding alkali metal hydroxide ions within a polysaccharide or polymer gel. Surrounding the third layer is at least one outer gel layer. The fourth and third layers dissolve in a low pH environment and release the fat soluble antioxidant and ions in the seed granule fissures.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: November 7, 2017
    Inventors: Steven Loyd, George Blouin, Newsha Farahani, Robert Burns
  • Patent number: 9730896
    Abstract: A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drag, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: August 15, 2017
    Assignee: ADARE PHARMACEUTICALS, INC.
    Inventors: Gopi M Venkatesh, Ken Kangyi Qian, Shyam Vangala, James M Clevenger, Donald Guenther
  • Patent number: 9566287
    Abstract: The present invention relates to a once daily pharmaceutical composition comprising doxycycline and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline pharmaceutical composition with or without food. A process of preparing such pharmaceutical composition is also provided.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: February 14, 2017
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Ravish Kumar Sharma, Pulak Kumar Metia, Ravinder Singh, Rajesh Srikrishan Shear, Anuj Kumar Fanda, Satish Kumar Jain, Romi Barat Singh, Swarna Pappu, Prabhakar Konatham, Pruthvipathy Katikaneni, Dileep Jami
  • Patent number: 9561242
    Abstract: The present invention relates to a once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients. The invention further provides a method of treatment of rosacea by administering such pharmaceutical composition. A process of preparing such pharmaceutical composition is also provided.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: February 7, 2017
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Ravish Kumar Sharma, Pulak Kumar Metia, Ravinder Singh, Rajesh Srikrishan Shear, Anuj Kumar Fanda, Satish Kumar Jain, Romi Barat Singh, Swarna Pappu, Prabhakar Konatham, Pruthvipathy Katikaneni, Dileep Jami
  • Patent number: 9511031
    Abstract: The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduced side effects such as nausea and irritation.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: December 6, 2016
    Assignee: Mayne Pharma International Pty. Ltd.
    Inventors: Stefan Lukas, Angelo Lepore, Stuart Mudge
  • Patent number: 9463196
    Abstract: The present invention relates to a once daily tablet comprising doxycycline at sub-antibiotic dose and one or more pharmaceutically acceptable excipients, wherein the tablet exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline tablet with or without food. A process of preparing the tablet is also provided.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 11, 2016
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Ravish Kumar Sharma, Pulak Kumar Metia, Ravinder Singh, Rajesh Srikrishan Shear, Anuj Kumar Fanda, Satish Kumar Jain, Romi Barat Singh, Swarna Pappu, Prabhakar Konatham, Pruthvipathy Katikaneni, Dileep Jami
  • Patent number: 9457008
    Abstract: The present invention provides a joint product comprising synephrine and topiramate, in which the synephrine or salt thereof is administered in form of rapid-release preparation, preferably rapid-release pellet, having daily dose of 2 mg to 25 mg, preferably 5 mg to 20 mg; the topiramate is administered in form of sustained-release or controlled-release preparation, preferably sustained-release pellet, having daily dose of 20 mg to 100 mg, preferably 23 mg to 92 mg. The composition is used for treatment of obesity or other diseases associated with obesity.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: October 4, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Chunsheng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang
  • Patent number: 9439860
    Abstract: Various fenofibrate dosage forms contain a plurality of beads or particles, where the beads or particles include a pharmaceutical composition comprising fenofibrate; from 0.3% to 10% by weight of the beads or particles of a surfactant; and from about 5% to about 15% by weight of the beads or particles of a water soluble or water dispersible cellulosic binder. The mass ratio of the drug to the binder in the dosage form is between about 3.5:1 and 4.5:1; and the dosage form produces a first Cmax in vivo that is between about 10% and about 50% higher than a comparative Cmax produced by a comparative dosage form. The comparative dosage form comprises the drug and the binder in a ratio of between about 5:1 and 15:1.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: September 13, 2016
    Assignee: Mylan, Inc.
    Inventors: Sarat C. Chattaraj, Glenn Allen Redelman, Andrew Alan Shaw
  • Patent number: 9132092
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) 50% to 99% of doxycycline as an immediate-release portion; (ii) 1% to 50% of doxycycline as a controlled-release portion; and (iii) one or more pharmaceutically acceptable excipients; wherein the pharmaceutical composition provides a total daily dosage of 40 mg when administered once daily. It also relates to process for preparation of the pharmaceutical composition and its use for treating rosacea.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: September 15, 2015
    Assignee: RANBAXY LABORATORIES LIMITED
    Inventors: Ravish Kumar Sharma, Pulak Kumar Metia, Ravinder Singh, Rajesh Srikrishan Shear, Anuj Kumar Fanda, Satish Kumar Jain, Romi Barat Singh, Swarna Pappu, Prabhakar Konatham, Pruthvipathy Katikaneni
  • Patent number: 9044398
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: June 2, 2015
    Assignee: Collegium Pharmaceutical, Inc.
    Inventors: Jane Hirsh, Alexander M. Klibanov, Timothy M. Swager, Stephen L. Buchwald, Whe Yong Lo, Alison Fleming, Roman V. Rariy
  • Patent number: 9034902
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 19, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Publication number: 20150104506
    Abstract: The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.
    Type: Application
    Filed: April 18, 2013
    Publication date: April 16, 2015
    Applicant: CONTERA PHARMA APS
    Inventors: John Bondo Hansen, Mikael S. Thomsen, Jens D. Mikkelsen, Peter Gudmund Nielsen, Mads Kreilgaard
  • Patent number: 8992973
    Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: March 31, 2015
    Assignee: Alkermes Science One Limited
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell, Sharon Hamm
  • Patent number: 8980320
    Abstract: A film coating agent for a solid formulation includes a water-soluble cellulose derivative, swelling clay, a cationic surfactant, and a fatty acid, wherein mass ratio of the swelling clay to the water-soluble cellulose derivative is 2:8 to 8:2, and content of the cationic surfactant is not less than 0.5 equivalents and not more than 3.0 equivalents relative to a cation exchange equivalent of the swelling clay.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: March 17, 2015
    Assignee: Toray Industries, Inc.
    Inventors: Ryoji Yoshii, Yuki Hayashi, Yuki Fujisaki
  • Patent number: 8974820
    Abstract: The invention provides an apparatus for producing soft gel capsules having encapsulated therein microparticles, nanoparticles and fluids, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies; (d) a liquid fill system (medicine pump system); (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) one or more microgranule or nanogranule feeders located on each side of the rotary dies, said feeders being synchronized to rotate at the same tangential speed as the rotary dies.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: March 10, 2015
    Assignee: Procaps SAS
    Inventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Willmer Herrera
  • Patent number: 8956648
    Abstract: The present invention provides pharmaceutical photosensitizer-loaded nanoparticle formulations and their methods of preparation for photodynamic therapy, comprising a hydrophobic or hydrophilic photosensitizer, nanoparticulate calcium phosphate and in certain cases auxiliary reagents such as stabilizers. The calcium phosphate-based nanoparticle formulations of the present invention provide excellent storage stability and therapeutically effective amounts of photosensitizer for intravenous or topical administration. In a preferred embodiment, tetrapyrrole derivatives such as porphyrins, chlorins and bacteriochlorins, are the preferred hydrophobic photosensitizers to be formulated in calcium phosphate nanoparticle formulations for photodynamic tumor therapy. Additionally, 5,10,15,20-tetrakis(4-phosphonooxyphenyl)porphine (pTPPP) is a preferred hydrophilic photosensitizer for photodynamic tumor therapy.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: February 17, 2015
    Assignee: Biolitec PharmaMarketing Ltd
    Inventors: Burkhard Gitter, Susanna Gräfe, Arno Wiehe, Volker Albrecht, Matthias Epple, Janine Schwiertz, Kathirvel Ganesan
  • Patent number: 8951557
    Abstract: Disclosed are a sustained release solid formulation comprising a drug, for example, oxycodone or its pharmaceutically acceptable salt, in a water-insoluble matrix, which comprises a wax type excipient and copovidone, and thus, has increased compressibility and fluidity and reduced adhesiveness, and a method of preparing the same.
    Type: Grant
    Filed: April 28, 2008
    Date of Patent: February 10, 2015
    Assignee: Hana Pharm. Co. Ltd.
    Inventors: Shajoung Chang, Oak Choi
  • Publication number: 20150037405
    Abstract: The present invention relates to pharmaceutical compositions of levodopa and carbidopa. In particular, the invention relates to modified release pharmaceutical compositions of levodopa and carbidopa with at least one organic acidic excipient. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of Parkinson's disease.
    Type: Application
    Filed: August 4, 2014
    Publication date: February 5, 2015
    Inventors: Sushrut Krishnaji Kulkarni, Pavak Rajnikant Mehta, Sameer Sagar Kochar, Krishnakumar Vinubhai Patel
  • Publication number: 20150010625
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Application
    Filed: September 24, 2014
    Publication date: January 8, 2015
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Patent number: 8927010
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: January 6, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 8916588
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: December 23, 2014
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Publication number: 20140370085
    Abstract: An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
    Type: Application
    Filed: June 17, 2014
    Publication date: December 18, 2014
    Inventors: Kathlene Powell, Ramesh Muttavarapu
  • Patent number: 8895061
    Abstract: The present invention provides compositions comprising carisoprodol or pharmaceutically acceptable salts, esters or derivatives thereof. In certain embodiments, the invention provides pharmaceutical compositions comprising the skeletal muscle relaxant carisoprodol and one or more additional active agents, such as one or more nonsteroidal antiinflammatory drugs (NSAIDs). The invention further provides methods of use of such compositions in preventing, alleviating and/or treating musculoskeletal pain, muscle spasms, or other non-malignant painful conditions including methods in which the circulating levels of the active pharmaceutical form of carisoprodol are controlled by use of extended- or controlled-release formulations or by strict control of dosage regimen, so as to reduce the level of somnolence observed with other muscle relaxant compositions.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: November 25, 2014
    Assignee: Meda Pharmaceuticals Inc.
    Inventors: Gul Balwani, Harry J. Sacks, Bryan A. Roecklein, Benjamin Johns
  • Patent number: 8883204
    Abstract: The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: November 11, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Robert P. Flath, John K. Masselink
  • Patent number: 8871275
    Abstract: The present invention deals with extended release pharmaceutical compositions comprising tolterodine, wherein the composition comprises: a) a drug layer comprising tolterodine tartrate, monosaccharide and/or disaccharide on an inert core; or a drug core comprising tolterodine tartrate, monosaccharide and/or disaccharide; and b) a polymer layer comprising extended release polymer(s). The invention also provides a process for the preparation of the above mentioned composition.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: October 28, 2014
    Assignee: Inventia Healthcare Private Limited
    Inventors: Sunil Beharilal Jaiswal, Ankur Janak Shah
  • Patent number: 8871235
    Abstract: The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: October 28, 2014
    Assignee: Synergy Biomedical LLC
    Inventor: Mark D. Borden
  • Patent number: 8865021
    Abstract: The present invention relates to compositions containing at least one cationic peptide active agent, at least one neutral structure forming amphiphile, at least one anionic structure forming amphiphile and optionally at least one solvent wherein the composition is in the form of a non-lamellar phase structure and/or forms a nonlamellar phase structure on exposure to body fluids. The invention also relates to methods for protecting peptides from enzymic degredation in vivo and to compositions in which the peptide active agent is so protected.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: October 21, 2014
    Assignee: Camurus AB
    Inventors: Fredrik Joabsson, Fredrik Tiberg
  • Publication number: 20140287037
    Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).
    Type: Application
    Filed: January 17, 2014
    Publication date: September 25, 2014
    Applicant: UPSHER-SMITH LABORATORIES, INC.
    Inventors: Sarah Michelle Betterman, Jaidev Srinivas Tantry, Laura Marie Patrick
  • Patent number: 8840923
    Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: September 23, 2014
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
  • Patent number: 8808736
    Abstract: A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: August 19, 2014
    Assignee: Zx Pharma, LLC
    Inventors: Syed Shah, Daniel Hassan, Fred Hassan
  • Patent number: 8795721
    Abstract: A device for delivering a substance in situ in a body comprising at least one permeable expandable container having a first dimension and a second dimension and having contained therein the substance to be delivered; and at least one expandable particle comprising a swellable material contained within the container and capable of expanding when contacted with a fluid; whereby when the device is positioned in situ, bodily fluid permeates the container causing the at least one expandable particle contained therein to swell and the container to expand from the first dimension to the second dimension so that the device remains in situ for a period of time sufficient to achieve the desired delivery of the substance is provided.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: August 5, 2014
    Assignee: Eatlittle Inc.
    Inventors: Martin Pavlov Mintchev, Orly Yadid-Pecht, Michel Fattouche
  • Patent number: 8770201
    Abstract: Condoms having an elastomeric layer and coating containing an anhydrous warming lubricant and at least one or more ingredients dispersed therein, the coating being disposed on one or both surfaces are provided. The ingredients disposed on the elastomeric layer can be solid particles or encapsulated ingredients that are insoluble in the anhydrous warming lubricant and soluble in water. Methods of producing and using these condoms are also provided.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: July 8, 2014
    Assignee: GlycoBioSciences Inc.
    Inventors: Michael S. Zedalis, Beng Sim Chuah, David M. Lucas, Angela M. Shiokawa, Jose R. Siqueira, Dave Narasimhan
  • Patent number: 8758813
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In one embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: June 24, 2014
    Assignee: Collegium Pharmaceutical, Inc.
    Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander M. Klibanov
  • Patent number: 8747900
    Abstract: The invention relates to a pharmaceutical composition comprising cefuroximaxetil and at least one carrageenan selected from the group consisting of ?-carrageenan, ?-carrageenan and -carrageenan. The invention furthermore relates to pellets, to a multiparticulate, pharmaceutical dosage form and to a novel crystalline modification of cefuroximaxetil.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: June 10, 2014
    Assignee: Gruenenthal GmbH
    Inventors: Iris Ziegler, Andreas Fischer
  • Patent number: 8741343
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: June 3, 2014
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Patent number: 8722083
    Abstract: Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: May 13, 2014
    Assignee: Mylan, Inc.
    Inventors: Sarat C. Chattaraj, Glenn Allen Redelman, Andrew Alan Shaw
  • Patent number: 8722650
    Abstract: An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: May 13, 2014
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Mitchell Wortzman, R. Todd Plott, Steven B. Newhard, David Watt
  • Publication number: 20140127291
    Abstract: Disclosed herein is an extended release liquid pharmaceutical composition comprising extended release particles dispersed in a liquid medium. The extended release particles comprise acetaminophen dispersed or encapsulated in a water insoluble polymer and/or wax to provide an extended release dosage form of acetaminophen. The liquid medium comprises water, an active pharmaceutical ingredient in immediate release form and, optionally, excipients. The composition is storage stable for at least 6 months at 40° C. and 75% relative humidity.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 8, 2014
    Applicant: MAYNE PHARMA INTERNATIONAL PTY LTD
    Inventor: Angelo Mario Morella
  • Publication number: 20140112985
    Abstract: This invention relates to prophylactic and/or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its microbial content to the distal small intestine and/or colon in high quantities and density, which is a “normalized” approach to repopulate the colonic flora as a method of prevention and/or treatment of, for example, Clostridium difficile colitis.
    Type: Application
    Filed: October 22, 2012
    Publication date: April 24, 2014
    Applicant: POLONEZ THERAPEUTICS LLC
    Inventors: Wieslaw J. Bochenek, Michael L. Corrado
  • Patent number: 8701879
    Abstract: A capsule-in-capsule system comprising at least two segregated chemical reactants is described. An inner capsule contains one reactant and is itself contained, with a second chemical reactant, in an outer capsule. The inner capsule and its contents is fabricated first; then it is incorporated into the second reactant; and the combination of the second reactant and inner capsule is encapsulated in the outer capsule. The reactants may be hydrophobic or hydrophilic and present as fluids, solids or combinations of solid(s) and fluids(s). When subjected to suitably high pressure, the capsule wall materials will fracture or rupture, releasing and preferably mixing all encapsulates to enable their prompt reaction. The utility of the invention is illustrated by its application to development of a corrosion inhibiting passive film on magnesium auto body material and to the adhesive bonding of members where precise positioning is desired.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: April 22, 2014
    Assignee: GM Global Technology Operations LLC
    Inventors: Tao Xie, Anil K. Sachdev
  • Patent number: 8685446
    Abstract: The invention relates to microcapsules, and a continuous micro-encapsulation water-in-oil-in-water microencapsulation process through in situ and interfacial polymerization of the emulsion. The formulation comprises a continuous water phase having a dispersion of microcapsules which contain oil drops and wherein the inside of each oil phase drop—containing optionally oil-soluble materials—there is a dispersion of water, or aqueous extract or water dispersible material or water soluble material. The oil drops are encapsulated with a polymerisable material of natural origin. Such microcapsules are appropriated for spray-dry processes, to be used as dry powder, lyophilised, self-emulsifiable powder, gel, cream and any liquid form. The active compounds included in the microcapsules are beneficial to the health and other biological purposes.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: April 1, 2014
    Inventors: Victor Casana-Giner, Miguel Gimeno-Sierra, Barbara Gimeno-Sierra, Martha Moser
  • Patent number: 8685443
    Abstract: A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: April 1, 2014
    Assignee: Alpharma Pharmaceuticals LLC
    Inventor: Garth Boehm
  • Patent number: 8668932
    Abstract: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: March 11, 2014
    Assignee: Andrx Pharmaceuticals, LLC
    Inventors: Manesh Dixit, Xiu-Xiu Cheng, Avinash Nangia, Chin Ming Chen
  • Patent number: 8663682
    Abstract: The present invention relates to a coated particle of active substance comprising a core, said core comprising the active substance and an acidic compound, said core being coated with a taste masking coating based on a polymer which is soluble at pH of 5 or less, and which is permeable at pH above 5.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: March 4, 2014
    Assignee: Ethypharm
    Inventors: Philippe Chenevier, Dominique Marechal